Similar to AHA/ACC, the Canadian Cardiovascular Society/Canadian Heart Failure Society’s guidelines recommended the prescription of SGLT2 in patients with HFrEF (LVEF < 40%) and without coexisting diabetes to reduce the risk of hospitalization and cardiovascular mortality [73]. The gene discussed is SLC5A2; the disease is heart failure.